Skip to main content
SpringerLink
Log in

Antiandrogen Withdrawal Syndrome Associated with Prostate Cancer Therapies

Incidence and Clinical Significance

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The antiandrogen withdrawal syndrome is a well established phenomenon in prostate cancer. It is widely accepted that a subset of patients will benefit from the withdrawal of antiandrogen or steroidal hormone from hormonal therapy, exhibiting decreasing prostate-specific antigen (PSA) values and clinical improvement. The pathophysiology of antiandrogen withdrawal syndrome is not completely understood, although androgen receptor gene mutations seem to be the likely explanation. Currently, it is not possible to identify the subset of patients whose tumours will respond to antiandrogen or steroid withdrawal. Tumours that will respond may be classified as androgen-independent and hormone-sensitive tumours as opposed to androgen-independent and hormone-insensitive tumours that do not respond. Patients who respond to antiandrogen withdrawal experience approximately 6 months with improved quality of life; however, it is unknown if this translates into prolonged survival. At the very least, antiandrogen withdrawal offers a therapeutic modality that is not associated with adverse effects and improves quality of life even if only for a very limited time.

Recent reports suggest that adding a secondary hormonal therapy such as aminoglutethimide, ketoconazole or steroidal hormones may enhance the response rate and prolong response time to the antiandrogen withdrawal syndrome. However, unless there is proof that this secondary hormonal manipulation prolongs survival, maintenance of quality of life is mandatory because of the possible adverse effects from these potent drugs.

The fact that about 30% of patients will respond to antiandrogen or steroid withdrawal in hormone refractory prostate cancer must be taken into account in clinical trials of new cytotoxic agents which have been and will be conducted. Cessation of flutamide for at least 4 weeks and, in the case of bicalutamide, even 8 weeks, is mandatory before antiandrogen withdrawal syndrome can be excluded as the cause of decreasing PSA values.

The antiandrogen withdrawal syndrome offers another piece of the puzzle of prostatic carcinoma, but at the same time it demonstrates how different advanced prostate cancer cells may react to therapeutic strategies and, therefore, hormone refractory prostate cancer remains a difficult challenge which must be solved in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Crawford ED, DeAntonio EP, Labrie F, et al. Endocrine therapy of prostate cancer: optimal form and appropriate timing. J Clin Endocrin and Metab 1995; 80: 1062–6

    Article  CAS  Google Scholar 

  2. Huggins C, Hodges CV. Studies on prostatic cancer, effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7

    CAS  Google Scholar 

  3. Schulze H, Isaacs JT, Senge T. Inability of complete androgen blockade to increase survival of patients with advanced prostate cancer as compared to standard hormonal therapy. J Urol 1987; 137: 909–11

    PubMed  CAS  Google Scholar 

  4. Sogani PC, Fair WR. Treatment of advanced prostatic cancer. Urol Clin North Am 1987; 14: 353–71

    PubMed  CAS  Google Scholar 

  5. Crawford ED, Eisenberger MA, McLeod DG, et al. Acontrolled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24

    Article  PubMed  CAS  Google Scholar 

  6. Wang MC, Valenzuela IA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–63

    PubMed  CAS  Google Scholar 

  7. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907–23

    PubMed  CAS  Google Scholar 

  8. Kelly WK, Scher HI. Prostate-specific antigen decline after antiandrogen withdrawal. J Urol 1993; 149: 607–9

    PubMed  CAS  Google Scholar 

  9. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408–10

    Article  PubMed  CAS  Google Scholar 

  10. Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J Urol 1995; 153: 1070–2

    Article  PubMed  CAS  Google Scholar 

  11. Huan SD, Gerridzen RG, You J, et al. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49: 632–4

    Article  PubMed  CAS  Google Scholar 

  12. Sella A, Flex D, Sulkes A, et al. Antiandrogen withdrawal syndrome with cyproterone acetate. Urology 1998; 52: 1091–3

    Article  PubMed  CAS  Google Scholar 

  13. Akakura K, Akimoto S, Furuya Y, et al. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. Eur Urol 1998; 33: 567–71

    Article  PubMed  CAS  Google Scholar 

  14. Bissada NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbesterol. J Urol 1995; 153: 1944–5

    Article  PubMed  CAS  Google Scholar 

  15. Dawson NA, McLoed DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153: 1946–7

    Article  PubMed  CAS  Google Scholar 

  16. Collinson MP, Daniel F, Tyrrell CJ, et al. Response of carcinoma of the prostate to withdrawal of flutamide. Br J Urol 1994; 72: 662–3

    Article  Google Scholar 

  17. Barthelemy Y, Colombel M, Gasman D, et al. Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape. Prog Urol 1996; 6: 93–7

    PubMed  CAS  Google Scholar 

  18. Kelly WK, Slovin S, Scher HI. Steroid Hormone withdrawal syndromes. Urol Clin North Am 1997; 24: 421–31

    Article  PubMed  CAS  Google Scholar 

  19. Wilding G, Cheng M, Gelman EP. Aberrant response in vitro of hormone responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 103–14

    Article  PubMed  CAS  Google Scholar 

  20. Veldscholte J, Ris-Stalpers C, Kuipers GG, et al. Amutation in the ligand binding domain of the androgen receptor of human LNCaP cells affect binding characteristics and response to anti-androgens. Biochem Biophys Res Common 1990; 173: 534–43

    Article  CAS  Google Scholar 

  21. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541–50

    Article  PubMed  CAS  Google Scholar 

  22. Gaddipati GP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancer. Cancer Res 54: 2862–4

  23. Newmark JR, Hardy EO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Nat Acad Sci USA 1992; 89: 6319–23

    Article  PubMed  CAS  Google Scholar 

  24. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer: Comparison of receptor content and response to hormonal therapy. Cancer 1991; 67: 3057–64

    Article  PubMed  CAS  Google Scholar 

  25. Kleinerman DI, Troncoso P, Pisters LL, et al. Expression and structure of the androgen receptor in bone metastases of hormone refractory prostate cancer. J Urol 1996; 155: 1254A

    Google Scholar 

  26. Klocker H, Culig Z, Hobisch A, et al. Androgen receptor mutations in prostate cancer. In: Wirth M, Altwein JE, Schmitz-Drager B, et al., editors. Molecular biology of prostate cancer. Berlin: Walter de Gruyter, 1998: 81–8

    Google Scholar 

  27. Suzuki H, Akakura K, Komiya A, et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29: 153–88

    Article  PubMed  CAS  Google Scholar 

  28. The androgen receptor gene mutations database. Available online at URL: http://www.mcgill.ca/androgendb/

  29. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401–6

    Article  PubMed  CAS  Google Scholar 

  30. Newling DW, Dennis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 1993; 72(12 Suppl.): S3793–8

    Article  Google Scholar 

  31. Scher HI, Steineck G, Kelly WK. Hormone-refractory (“D3”) prostate cancer: refining the concept. Urology 1995; 46: 142–8

    Article  PubMed  CAS  Google Scholar 

  32. Scher HI, Zhang ZF, Cohen L, et al. Hormonally relapsed prostatic cancer: Lessons from the flutamide withdrawal syndrome. Adv Urol 1995; 8: 61–95

    Google Scholar 

  33. Herrada J, Dieringer P, Logothetis CJ. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 1996; 155: 620–3

    Article  PubMed  CAS  Google Scholar 

  34. Breul J, Paul R. Das “Antiandrogen-Entzugssyndrom”. Erste klinische Erfahrung und Literaturubersicht. Akt Urol 1996; 27: 267–70

    Article  Google Scholar 

  35. Figg WD, Sartor O, Cooper MR, et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995; 98: 412–4

    Article  PubMed  CAS  Google Scholar 

  36. Schellhammer PF, Venner P, Haas GP, et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157: 1731–5

    Article  PubMed  CAS  Google Scholar 

  37. Hornak M, Bardos A, Concalves F. The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens. Rozhl Chir 1997; 76: 435–7

    PubMed  CAS  Google Scholar 

  38. Dupont A, Gomez J, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150: 908–13

    PubMed  CAS  Google Scholar 

  39. Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of ‘hormone-refractory’ prostate cancer. J Natl Cancer Inst 1994; 86: 222–7

    Article  PubMed  CAS  Google Scholar 

  40. Figg WD, Dawson N, Middleman A, et al. Flutamide withdrawal and concomitant aminoglutethimide in patients with hormone refractory prostate cancer. Acta Oncologica 1996; 35: 763–5

    Article  PubMed  CAS  Google Scholar 

  41. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997; 80: 1755–9

    Article  PubMed  CAS  Google Scholar 

  42. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995; 76: 1428–34

    Article  PubMed  CAS  Google Scholar 

  43. Furuya Y, Akimoto S, Akakura K, et al. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol Int 1998; 60: 28–32

    Article  PubMed  CAS  Google Scholar 

  44. Small EJ, Baron AD, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 4: 1204–7

    Google Scholar 

  45. Reese DM, Small EJ. Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin North Am 1999; 26: 311–21

    Article  PubMed  CAS  Google Scholar 

  46. Dawson N, Cooper MR, Figg WD, et al. Antitumor activity of suramin in hormone-refractory prostate cancer when hydrocortisone treatment and flutamide withdrawal are prospectively controlled for as potentially confounding variables. Cancer 1995; 76: 453–62

    Article  PubMed  CAS  Google Scholar 

  47. Figg WD, Kroog G, Duray P, et al. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Cancer 1997; 79: 1964–8

    Article  PubMed  CAS  Google Scholar 

  48. Small EJ, Marshall ME, Reyno L, et al. Superiority of suramin plus hydrocortisone (S+H) over placebo plus hydrocortisone (P+H): Results of a multicenter double-blind phase III study in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1998; 17: 308–12

    Google Scholar 

  49. Nishiyma T, Terunuma M. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int J Urol 1998; 5: 44–7

    Article  Google Scholar 

  50. Storlie JA, Buckner JC, Wiseman GA, et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995; 76: 96–100

    Article  PubMed  CAS  Google Scholar 

  51. Scher IH, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566–72

    PubMed  CAS  Google Scholar 

  52. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 2167–72

    PubMed  CAS  Google Scholar 

  53. Fowler JE, Whitmore WF. Consideration for the use of testosterone with systemic chemotherapy for prostatic cancer. Cancer 1982; 49: 1373–7

    Article  PubMed  Google Scholar 

  54. Manni A, Bartholomew M, Caplan R, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988; 6: 1456–66

    PubMed  CAS  Google Scholar 

  55. Hall MC, Fritzsch RJ, Sagalowsky AI, et al. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999; 53: 898–902

    Article  PubMed  CAS  Google Scholar 

  56. Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group Report. J Clin Oncol 1994; 12: 1868–75

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Technische Universität Munich, Klinikum rechts der Isar, Ismaninger Str. 22, 81675, Munich, Germany

    Roger Paul & Juergen Breul

Authors
  1. Roger Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juergen Breul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger Paul.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paul, R., Breul, J. Antiandrogen Withdrawal Syndrome Associated with Prostate Cancer Therapies. Drug-Safety 23, 381–390 (2000). https://doi.org/10.2165/00002018-200023050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200023050-00003

Keywords

Search

Navigation